Journal Information
Vol. 4. Issue 1.
Pages 51-64 (January - February 1998)
Share
Share
Download PDF
More article options
Vol. 4. Issue 1.
Pages 51-64 (January - February 1998)
Open Access
Marcadores de actividade das doenças do interstício pulmonar: situação actual*
Visits
4375
Pedro Silveira**
Interno Complementar de Pneumologia do Hospital de S. João - Porto (Director: Prof. J. Agostinho Marques)
This item has received

Under a Creative Commons license
Article information
RESUMO

As doenças do intersticio pulmonar abrangem um vasto grupo de entidades, com critérios de diagnóstico relativamente bem definidos, mas que apresentam dificuldades na sua abordagem clinica, nomeadamente na detinição do seu estado de actividade. Este termo significa progressão da doença, o que não e sinónimo de extensão da doença. A procura de marcadores de actividade das diferentes doenças do intersticio tem sido uma constante, o que se reflecte num grande número de trabalbos de investigação sobre este tema. Neste texto, fazse uma revisão dos estudos mais recentes· e dos marcadores com potencial interesse num futuro a curto/médio prazo, com a certeza de que ainda não existe um marcador, que, por si só, seja suficientemente especifico e sensivel para definir o estado de actividade das doenças do intersticio pulmonar.

Palavras-chave:
Marcadores de actividade
Sarcoidose
Fibrose pulmonar
ABSTRACT

Interstitial lung diseases include a large group of pathologies with well defined diagnostic criteria, but they exhibit a lot of difficulties in their handling, namely in defining their activity state. Activity means progression, which is different from disease extension. The search of activity markers has been a constant, which is reflected by a great number of investigation papers concerning this subject. In this work, a revision of the most recent studies is made, focusing on the markers with potential interest in a short/medium period of time. At this moment, we still don't have a marker that, alone, is sensitive and. specifiic enough to define the state of activity of interstitial lung diseases.

Key-words:
Activity markers
Sarcoidosis
Pulmonary fibrosis
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
R. Winterbauer.
Current concepts in and modes for measurement of activity in interstitial lung disease.
Curr Opinion Pulm Med, 1 (1995), pp. 358-362
[2.]
M. Remy-Jardin, F. Giraud, J. Remy, et al.
Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment.
Radiology, 191 (1994), pp. 675-680
[3.]
M. Akira, H. Hamada, M. Sakatani, et al.
CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis.
Am J Roentgenol, 168 (1997), pp. 79-83
[4.]
A. Drago, M. Battaglia, M.R. Rimondi, et al.
Signs of inflammatory activity in thoracic sarcoidosis. A high-resolution computerized tomography study.
Radiol Med (Torino), 89 (1995), pp. 57-64
[5.]
A. Oberstein, H. von Zitzewitz, F. Schweden, et al.
Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography.
Sarcoidosis Vase Diffuse Lung Dis, 14 (1997), pp. 65-72
[6.]
J. Polák, J. Homolka, M. Vasáková.
High-resolution computer tomography in the diagnosis of cryptogenic fibrosing alveolitis. Correlation with pulmonary function and bronchoalveolar lavage.
Cas Lek. Cesk, 135 (1996), pp. 417-422
[7.]
R.S. Crausman, D.A. Lynch, R.L. Mortenson, et al.
Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis.
Chest, 109 (1996), pp. 131-137
[8.]
M. Kitaichi, K. Nishimura, H. Itoh, et al.
Pulmonary lymphangioleiomyornatosis: a report of 46 patients including a clinicopathologic study of prognostic factors.
Am J Respir Crit Care Med, 151 (1995), pp. 527-533
[9.]
K.N. Lee, D.L. Levin, W.R. Webb, et al.
Pulmonary alveolar proteinosis. High resolution CT, chest radiographic, and functional correlations.
Chest, 111 (1997), pp. 989-995
[10.]
J. Maná, A. Salazar, R. Pujol, et al.
Are the pulmonary function tests and the markers of activity helpful to establish the prognosis of sarcoidosis?.
Respiration, 63 (1996), pp. 298-303
[11.]
R.A. De Remee.
Sarcoidosis.
Mayo Clin Proc, 70 (1995), pp. 177-181
[12.]
O.P. Sharma, S. Alam.
Diagnosis. Pathogenesis, and treatment of sarcoidosis.
Curr Opinion Pulm Med, 1 (1995), pp. 392-400
[13.]
H. Takizawa, M. Satoh, H. Okazaki, et al.
Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters.
Clin Exp Immunol, 107 (1997), pp. 175-181
[14.]
R.E. Girgis, M.A. Basha, M. Maliarik, et al.
Cytokincs in the bronchoalvcolar lavage fluid of patients with active pulmonary sarcoidosis.
Am J Respir Crit Care Med, 152 (1995), pp. 71-75
[15.]
T. Yokoyama, T. Kanda, I. Kobayashi, et al.
Serum levels of interleukin-8 as a marker of disease activity in patients with chronic sarcoidosis.
J Med, 26 (1995), pp. 209-219
[16.]
H. Nakamura, S. Fujishima, Y. Wakj, et al.
Priming of alveolar macrophages for interleukin-8 production in patients with idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 152 (1995), pp. 1579-1586
[17.]
A.M. Southcott, K.P. Jones, D. Li, et al.
Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis.
Am J Respir Crit Care Med, 151 (1995), pp. 1604-1612
[18.]
M. Denis.
Proinflammatory cytokines in hypersensitivity pneumonitis.
Am J Respir Crit Care Med, 151 (1995), pp. 164-169
[19.]
I. Bäumer, G. Zissel, M. Schlaak, et al.
Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis.
Lung, 175 (1997), pp. 105-116
[20.]
Y. Ishji, S. Kitamura.
Elevated levels of soluble ICAM-1 in serum and BAL fluid in patients with active sarcoidosis.
Chest, 107 (1995), pp. 1636-1640
[21.]
A. Nakao, Y. Hasegawa, Y. Tsuchiya, et al.
Expression of cell adhesion molecules in the lungs of patients with idiopathic pulmonary fibrosis.
Chest, 108 (1995), pp. 233-239
[22.]
T. Fujishima, Y. Honda, N. Shijubo, et al.
Increased carcinocmbryonic antigen concentrations in sera and bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis.
Respiration, 62 (1995), pp. 317-321
[23.]
C.I. Jack, M.J. Jackson, I.D. Johnston.
Serum indicators of free radical activity in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 153 (1996), pp. 1918-1923
[24.]
D. Saleh, P.J. Barnes, A. Giaid.
Increased production of the potent oxidant peroxynirrite in the lungs of patients with idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 155 (1997), pp. 1763-1769
[25.]
K. Fujimoto, K. Kubo, S. Yamaguchi, et al.
Eosinophil activation in patients with pulmonary fibrosis.
Chest, 108 (1995), pp. 48-54
[26.]
J.P. Straub, G.J. Van Kamp, T.C. Van Maarsseveen.
Biochemical parameters in BAL of sarcoisosis.
Sarcoidosis, 12 (1995), pp. 51-57
[27.]
J.C. Weissler.
Southwestern Internal Medicine Conference: Sarcoidosis: immunology and clinical management.
Am J Med Sci, 307 (1994), pp. 233-245
[28.]
S. Kuroki, A. Ohta, N. Sueoka, et al.
Determination of various cytokines and type III procollagen aminopeptide levels in bronchoalveolar lavage fluid of the patients with pulmonary fibrosis: inverse correlation between type III procollagen aminopcptide and interferon-gamma in progressive patients.
Br J Rheumatol, 34 (1995), pp. 31-36
[29.]
N. Milman, M.S. Kristensen, K. Bentsen.
Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid from patients with pulmonary fibrosis.
APMIS, 103 (1995), pp. 749-754
[30.]
N. Milman, M.S. Kristensen, K. Bentsen, et al.
Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalvcolar lavage fluid in patients with pulmonary sarcoidosis.
Sarcoidosis, 12 (1995), pp. 38-41
[31.]
S. Andersen, L. Bjermer, P.K. Selbo, et al.
Extracellular phospholipase A2 expression in sarcoidosis.
Sarcoidosis Vase Diffuse Lung Dis, 13 (1996 Mar), pp. 70-76
[32.]
W.A. Wallace, S.E. Howie, D. Lamb, et al.
Tenascin immunoreactivity in cryptogenic fibrosing alveolitis.
J Pathol., 175 (1995), pp. 415-420
[33.]
C. Kuhn, R.J. Mason.
Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis.
Am J Pathol, 147 (1995), pp. 1759-1769
[34.]
I. Kotani, A. Sato, H. Hayakawa, et al.
Increased procoagulant and antitibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
Thromb Res, 77 (1995), pp. 493-504
[35.]
T. Nakayama, S. Hashimoto, E. Amemiya, et al.
Elevation of plasmasoluble tumour necrosis factor receptors (TNF-R) in sarcoidosis.
Clin Exp lmmunol, 104 (1996), pp. 318-324
[36.]
L. Zheng, H. Teschler, Jguzman, et al.
Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis.
Am J Respir Crit Care Med, 152 (1995), pp. 1061-1066
[37.]
I. Striz, L. Zheng, Y.M. Wang.
Soluble CD14 is increased in bronchoalveolar lavage of active sarcoidosis and correlates with alveolar macrophage membrane-bound CD 14.
Am J Respir Crit Care Med, 151 (1995), pp. 544-547
[38.]
V. De Rose, L. Trentin, M.T. Crivellari.
Release of prostaglandin E2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis.
Thorax, 52 (1997), pp. 76-83
[39.]
K.C. Meyer, R.A. Arend, M.V. Kalayoglu, et al.
Tryptophan metabolism in chronic inflammatory lung disease.
J Lab Clin Med, 126 (1995), pp. 530-540
[40.]
P. Silveira, M.C. Palmares, L. Delgado.
Lavagem broncoalvcolar: metodologia e aplicação clinica.
Rev Port Pneumol, 3 (1997), pp. 155-178
[41.]
K. Suzuki, N. Tamura, A. Iwase, et al.
Prognostic value of Ia+ T lymphocytes in bronchoalvcolar lavage fluid in pulmonary sarcoidosis.
Am J Respir Crit Care Med, 154 (1996), pp. 707-712
[42.]
E.N. Levin.
Endothelins.
N Engl J Mcd, 333 (1995), pp. 356-363
[43.]
M. Uguccioni, L. Pulsatelli, B. Grigolo, et al.
Endothelin-1 in idiopathic pulmonary fibrosis.
J Clin Pathol, 48 (1995), pp. 330-334
[44.]
M. Sofia, M. Mormile, S. Faraone, et al.
Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases.
Sarcoidosis, 12 (1995), pp. 118-123
[45.]
G.W. Hunninghake, A.R. Kalica.
Approaches to the treatment of pulmonary fibrosis.
Am J Respir Crit Care Med, 151 (1995), pp. 915-918
[46.]
F.X. McCormac, T.E. King, B.L. Bucher, et al.
Surfactant protein A predicts survival in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 152 (1995), pp. 751-759
[47.]
Y. Honda, Y. Kuroki, E. Matsuura.
Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids.
Am J Respir Crit Care Med, 152 (1995), pp. 1860-1866
[48.]
Y. Honda, Y. Kuroki, N. Shijubo.
Aberrant appearance of lung surfactant protein A in sera of patients with idiopathic pulmonary fibrosis and its clinical significance.
Respiration, 62 (1995), pp. 64-69
[49.]
O. Lesur, A.M. Bernard, R.O. Bégin, et al.
Clara cell protein (CC-16) and surfactant-associated protein A (SP-A) in asbestos-exposed workers.
Chest, 109 (1996), pp. 467-474
[50.]
A. Capelli, M. Lusuardi, C.G. Cerutti, et al.
Lung alkaline phosphatase as a marker of fibrosis in chronic interstitial disorders.
Am J Respir Crit Care Med, 155 (1997), pp. 249-253
[51.]
J. Kobayashi, S. Kitamura, et al.
KL-6: a serum marker tor interstitial pneumonia.
Chest, 108 (1995), pp. 311-315
[52.]
Y. Inoue, K. Nishimura, M. Shiode, et al.
Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis.
Tuber Lung Dis, 76 (1995), pp. 230-233
[53.]
J. Kobayashi, S. Kitamura.
Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis.
Chest, 109 (1996), pp. 1276-1282

Trabalho apresentado no XIII Congresso de Pneumologia da SPP, em Nov 97 em Lisboa, na sessão "Revisōes de literaturaPatologia do intersticio".

Copyright © 1998. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?